Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Health GroupHKSE:08225 Days Payable is 121.65 as of Dec. 2025, which is 18% below its 10-year median of 147.99. The stock has 4 warning signs investors should review. Among 189 Medical Diagnostics & Research companies, China Health Group ranks worse than 50.26% on this metric.
The historical rank and industry rank for China Health Group's Days Payable or its related term are showing as below:
HKSE:08225'
s Days Payable Range Over the Past 10 Years
Min: 12.77 Med: 147.99 Max: 1319.88
Current: 65.09
During the past 13 years, China Health Group's highest Days Payable was 1319.88. The lowest was 12.77. And the median was 147.99.
HKSE:08225's Days Payable is ranked worse than 50.26% of 189
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.09
vs HKSE:08225: 65.09
China Health Group's Days Payable
declined
from Dec. 2024 (123.05) to Dec. 2025 (121.65).
It may suggest that China Health Groupaccelerated paying its suppliers.
The historical data trend for China Health Group's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:08225 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, China Health Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Group Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, China Health Group's Days Payable distribution charts can be found below:
* The bar in red indicates where China Health Group's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
China Health Group's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Health Group (HKSE:08225) has a Days Payable of 121.65 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Health Group and its competitors. This is 18% below median its historical median of 147.99. Over the past decade, China Health Group's Days Payable has ranged from 12.77 to 1,319.88. According to the industry distribution chart, China Health Group ranks #95 out of 189 companies in the Medical Diagnostics & Research industry, placing it in the top 50.3%.
Is China Health Group's Days Payable too high?
China Health Group's current Days Payable of 121.65 is 18% below median its 10-year median of 147.99. Over the past 10 years, this metric has ranged from a low of 12.77 to a high of 1,319.88. The Medical Diagnostics & Research industry median Days Payable is 65.09. China Health Group's value of 121.65 is 86.9% above this industry median. Based on the distribution chart, China Health Group ranks #95 out of 189 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint.
How does China Health Group's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, China Health Group ranks #95 out of 189 companies for Days Payable. This places China Health Group in the lower half of its industry. The industry median Days Payable is 65.09. China Health Group's value of 121.65 is 86.9% above this benchmark. Historically, China Health Group's own Days Payable has ranged from 12.77 to 1,319.88 over the past decade. While the company's 10-year median is 147.99 vs. the industry median of 65.09, China Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 65.09, based on 189 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Health Group's current Days Payable of 121.65 is 86.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on China Health Group and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 65.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Health Group's current Days Payable is 121.65, which is 18% below median its own 10-year median of 147.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:08225) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.21, compared to a current price of HK$0.08 — trading 61.4% below its estimated fair value. The current Days Payable is 121.65, which is 18% below median its 10-year median of 147.99 and 86.9% above the Medical Diagnostics & Research industry median of 65.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For China Health Group (HKSE:08225), the current Days Payable is 121.65 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
China Health Group Inc is an investment holding company engaged in providing medical care facilities in the People's Republic of China. The company provides provision of post-launch market research, medical and medical market services (PM services), Provision of contracted pharmaceutical development services (PD services), Provision of contracted clinical research services (CR Services), drug technologies, and Other medical services. The majority of its revenue for the company comes from the provision of PM services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08225 has been successfully added to your 
